文献速递临床试验与 GCP医学人工智能与信息学

人工智能支持的无创测量减少大型骨科与创伤手术术中低血压:随机临床试验研究方案

AI-supported non-invasive measurement for intraoperative hypotension reduction in major Orthopedic and trauma surgery-study protocol for a randomized clinical trial.
PubMed 文献 · Trials · 2025-10-30

本单中心、随机、前瞻性干预试验将在吉森大学医院纳入150例45岁及以上接受大型骨科或创伤手术的患者,比较ClearSight系统联合基于低血压预测指数(HPI)的治疗算法与盲法连续心输出量监测的标准治疗对术中低血压发生率、持续时间及严重程度的影响,并评估术后急性肾损伤、非心脏手术后心肌损伤及术后谵妄等次要终点。

要点

  • 干预组采用ClearSight联合HPI治疗算法,对照组接受盲法连续心输出量监测的标准治疗。
  • 主要终点为术中低血压发生率、持续时间及严重程度,定义为MAP<65 mmHg至少1分钟。
  • 次要终点包括术后急性肾损伤(KDIGO标准)、非心脏手术后心肌损伤(高敏肌钙蛋白I)及术后谵妄。

核心结论

  • 本研究旨在证明术中血流动力学稳定性改善、低血压减少及术后并发症发生率降低,可能为骨科与创伤患者的无创连续监测树立新标准。

研究设计与样本

  • 单中心、随机、前瞻性干预试验,在吉森大学医院开展,纳入45岁及以上接受大型骨科或创伤手术的患者。
  • 计划招募150例患者(考虑潜在脱落),以提供足够把握度检测主要和次要终点的差异。
  • 参与者随机分为两组:干预组接受ClearSight系统联合基于HPI的治疗算法进行血流动力学管理;对照组接受标准治疗,同时接受连续心输出量监测但该监测对麻醉医师设盲,以确保所测血流动力学参数的可比性。

关键数值与推荐

  • 主要终点为术中低血压的发生率、持续时间及严重程度,术中低血压定义为MAP<65 mmHg至少1分钟,并以MAP<65 mmHg曲线下面积及MAP<65 mmHg的时间加权平均值(TWA)计算。
  • 次要终点包括术后急性肾损伤(按KDIGO标准测量)、非心脏手术后心肌损伤(采用高敏肌钙蛋白I检测)及术后谵妄的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraoperative hypotension (IOH) is a common complication in non-cardiac surgeries, with significant impacts on postoperative outcomes such as acute kidney injury (AKI), myocardial injury after non-cardiac surgery (MINS), and postoperative cognitive dysfunction (delirium). Traditional non-invasive blood pressure monitoring often results in blind gaps through the discontinuous measurement, potentially missing critical hypotensive events. This study investigates the efficacy of a non-invasive, continuous AI-supported technology using the Hypotension Prediction Index (HPI) system, designed to predict and mitigate IOH, in reducing the incidence and severity of IOH and related complications in major orthopedic and trauma surgeries. METHODS/DESIGN: This monocentric, randomized, prospective interventional trial will be conducted at the University Hospital Giessen. The study will include patients aged 45 years and older undergoing major orthopedic or trauma surgeries. Participants will be randomized into two groups: an intervention group receiving hemodynamic management using the ClearSight system in combination with a HPI-based treatment algorithm and a control group receiving standard care. The patients from the standard group also receive continuous cardiac output monitoring; however, this will be blinded to the anesthesiologist, to ensure the comparability of the measured hemodynamic parameters. The primary endpoint is the incidence, duration and severity of IOH, which is defined as MAP < 65 mmHg for at least one minute and which is calculated as the area under MAP < 65 mmHg and the time-weighted average (TWA) of MAP < 65 mmHg. Secondary endpoints include the occurrence of postoperative AKI (measured by KDIGO criteria), MINS (measured by high-sensitivity troponin I assays), and postoperative delirium. The study aims to recruit 150 patients, accounting for potential dropouts, to provide sufficient power to detect differences in the primary and secondary endpoints. CONCLUSION: This study aims to demonstrate improved intraoperative hemodynamic stability, with a reduction of hypotension and a reduced incidence of postoperative complications, potentially setting a new standard for non-invasive continuous monitoring in orthopedic and trauma patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT06291714. Registered on 4 March 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Habicher M, Kleymann R, Shakkour K, et al. AI-supported non-invasive measurement for intraoperative hypotension reduction in major Orthopedic and trauma surgery-study protocol for a randomized clinical trial. Trials. 2025. PMID: 41168839. doi:10.1186/s13063-025-09194-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。